Lv55
880 积分 2023-03-30 加入
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics
1天前
已完结
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
3天前
已完结
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
3天前
已完结
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
3天前
已完结
Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study
3天前
已完结
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
3天前
已完结
Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
3天前
已完结
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
6天前
已完结
Identifying effective computerized strategies to prevent drug–drug interactions in hospital: A user-centered approach
2个月前
已关闭
The prevalence of drug-drug interactions in cancer therapy and the clinical outcomes
2个月前
已完结
皖公网安备34019202002308
